Breaking News on Biopharmaceutical Development & Manufacturing

Top Headlines

Downstream test facility set to address scale-up issues and keep investment in UK

A downstream centre in Scotland will allow local biotechs to test product scale-up without outsourcing overseas, while complementing other Government-funded bioprocessing projects in the UK.

Europe OKs Samsung Bioepis’ Remicade biosimilar Flixabi

The European Commission (EC) has approved Samsung Bioepis’ Remicade (infliximab) biosimilar.

Autologous insulin developer Orgenesis forms Israeli cell therapy JV

Orgenesis and Atvio have formed a cell therapy contract manufacturing joint venture and are looking to procure a GMP facility in Israel.

Inflectra-maker Celltrion to expand biosimilar capacity by 170,000L

Celltrion will invest $275m at its biosimilar production site in Korea to ramp up capacity from 140,000L to 310,000L by 2021.

Safety board clears TxCell to restart Ovasave study that was halted last year

TxCell has been cleared to restart a Phase IIb trial of its candidate Crohn’s disease cell therapy by European regulators.

Thermo: FEI deal will complement mass spec portfolio

Thermo Fisher Scientific is to buy FEI Company for $4.2bn saying it will drive adoption of FEI’s technologies among its life sciences customers, particularly in biopharma.


By World Courier

Content Provided by World Courier

World Courier shares its insights on successful importation of clinical trial drugs into China

Getting a clinical trial drug into China is a complex business. Any discrepancies in paperwork or the physical shipment can lead to delays at customs or China Inspection & Quarantine. World Courier shares its experience for successful shipping.

Key Industry Events


Access all events listing

Our events, Shows & Conferences...